Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial.
Year: 2018
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Komal L. Jhaveri, Vicky Makker, Xin Victoria Wang, Alice P. Chen, Keith Flaherty, Barbara A. Conley, Peter J. O'Dwyer, Paul M. Williams, Stanley R. Hamilton, Lyndsay Harris, Lisa McShane, Lawrence Rubinstein, Robert James Gray, Shuli Li, Edith P. Mitchell, David Patton, Jeffrey Moscow, James A. Zwiebel, Carlos L. Arteaga, Shiuh-Wen Luoh
Institutions: New York University, Memorial Sloan Kettering Cancer Center, Harvard University, Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute, Massachusetts General Hospital, Abramson Cancer Center, University of Pennsylvania, Frederick National Laboratory for Cancer Research, The University of Texas MD Anderson Cancer Center, Thomas Jefferson University, Sidney Kimmel Cancer Center, Lexington Clinic, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Oregon Health & Science University
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2806006952